Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
   
Ask the Experts About

Choosing Your MedsChoosing Your Meds
           
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


Nevirapine warning
Jan 26, 2005

I just saw the warning about nevirapine from the FDA. http://www.thebody.com/fda/nvp_advisory.html

Can you explain it to me?Women with a CD4 count over 250 should avoid starting a regimen with nevirapine (Viramune), right? If they are on currently and doing ok it's ok, right?

Response from Dr. Young

Thanks for your post.

A small percentage of persons who start on nevirapine develop a very severe allergic reaction that result in liver injury (and very rarely death). The allergic reaction is tied to immune function, so paradoxically, persons with higher initial CD4 counts (such as women with CD4s greater than 250) are at higher risk-- hence the warning.

For persons who are currently taking nevirapine and are doing "ok", there is little or no additional risk and there is no need to discontinue the medication. BY



Previous
Thank you Benjamin
Next
GI side effects

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement